Skip to content

Exercise, nutrition and muscle quality

Randomized controlled trial to compare the impact of exercise and nutritional interventions on changes in skeletal muscle mass and function in obese patients with sarcopenia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/06/019941
Enrollment
140
Registered
2019-06-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E669- Obesity, unspecified

Interventions

Intervention1: Progressive resistance exercise: Progressive resistance exercise with nutritional intervention for a period of 6 months Control Intervention1: Standard physical activity: Standard physi

Sponsors

Submitted to ICMR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Individuals between 30-60 years of age with BMI >=25 kg/m2, diagnosed to have sarcopenia based on the following definition of sarcopenia: 1 Appendicular skeletal muscle mass/height2: Men 2 Hand grip strength Men: 3 SPPB 4 4-minute gait speed

Exclusion criteria

Exclusion criteria: 1 Known or recently diagnosed diabetes mellitus or coronary heart disease 2 Contraindication to aerobic exercise or progressive resistance training 3 Any severe acute or chronic illness, severe end organ dysfunction, post organ transplant 4 Known malignancy, HIV/ HBsAg/Anti HCV positivity 5 Chronic alcohol use ( >30 g/day in men and >20 g/day in women) or any other drug abuse 6 Use of any medications that may affect the muscle function or mass such as corticosteroids, anabolic steroids, protein supplements, performance enhancing medications etc. 7 Pregnancy and lactation, any physical deformity or loss of extremity

Design outcomes

Primary

MeasureTime frame
Improvement in muscle mass and function in sarcopenic individualsTimepoint: At the end of 6 months

Secondary

MeasureTime frame
Improvement in metabolic abnormalities such as insulin resistance, dyslipidemia and dysglycemiaTimepoint: At the end of 6 months

Countries

India

Contacts

Public ContactDr Naval K Vikram

A.I.I.M.S., New Delhi

navalvikram@gmail.com119810007331

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026